rPFS as a surrogate for OS in mHSPC #ProstateCancer Available now 👉 buff.ly/A8SymmS What does it mean for clinical practice? How should it guide treatment decisions? 📺 Join Neal Shore, MD @CURCMB & Alicia Morgans, MD @CaPsurvivorship

Join us for the Post-ASCO 2025 GI & ESMO Cancer Highlights! NOW LIVE AND ON DEMAND WATCH HERE👉https://bit.ly/3K9Zcsl This webinar brought to us by our collaborators at @VJOncology dives into key abstracts and breakthroughs in GI cancer from ASCO 2025.

The U.S. FDA has approved imlunestrant, an oral estrogen receptor antagonist, for the treatment of adults with ER+, HER2–, ESR1-mutated advanced or metastatic #BreastCancer that has progressed after at least one line of endocrine therapy. investor.lilly.com/news-release...

Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers with Different MET Exon 14 Skipping Mutations. www.jto.org/article/S155... This study evaluated NSCLC cases with MET exon 14 skipping (METex14) mutations

COLLEAGUES AT #ESMO25 🇩🇪 WELCOME to the #OncoAlert5k 🚨 REGISTER👉 oncoalert.m-pages.com/P3LU6F/the-o... SATURDAY October 18 7AM departure Meeting Point : Brandenburg Gate RUNNING ROUTE VIA Map My Run APP (QR code ) REGISTRATION Necessary. Event Open to Oncologists, Oncology Nurses and Advocates

NEWS FROM INDUSTRY 🚨 SOURCE: ROCHE Roche announced positive results from the evERA trial, showing giredestrant plus everolimus significantly improved progression-free survival in patients with ER+, HER2- advanced #BreastCancer previously treated with CDK4/6 inh & ET www.roche.com/media/releas...

Join us for an engaging discussion on rPFS as a surrogate for OS in patients with mHSPC 👉 library.mirrorsmed.org/index.php/ma... Hosted by Dr. Neal Shore (START Carolinas, Myrtle Beach, SC) and Dr. Alicia Morgans (Dana-Farber Cancer Institute, Boston, MA) and brought to you by Mirrors of Medicine.

FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection www.fda.gov/drugs/resour... The FDA approved pembrolizumab & berahyaluronidase alfa-pmph as a SC formulation for adult and pediatric patients with solid tumor indications already approved for IV pembrolizumab

The Post-ASCO 2025 GU Cancer Highlights virtual webinar by @VJOncology WATCH NOW On Demand 👉 buff.ly/bwTCZMd Featuring expert presentations and discussions on key GU cancer abstracts from ASCO 2025. @neerajaiims @ERPlimackMD @AndreaNecchi

rPFS as a surrogate for OS in mHSPC #ProstateCancer Available now 👉 library.mirrorsmed.org/index.php/ma... What does it mean for clinical practice? How should it guide treatment decisions? 📺 Join Neal Shore & Alicia Morgans for an in-depth discussion and real-world case insights.

Postoperative PCa Recurrence: Case-Based Discussion on Hormonal & Radiation Therapy 👉 Register now: us02web.zoom.us/webinar/regi... 🗓️ Thursday, September 25, 2025 🕕 18:00 CEST | Paris 🎙️ Speakers: Bertrand Tombal & Vérane Achard Hosted by Mirrors of Medicine

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Muscle-Invasive #BladderCancer ascopubs.org/doi/abs/10.1... Study presents international consensus recommendations from the IBCG & GSRGT on standardized outcome measures for evaluating bladder-sparing strategies in MIBC

Evaluation of efficacy and safety of sequential antibody drug conjugates (ADCs) in human epidermal growth factor 2 (HER2)-negative metastatic #BreastCancer link.springer.com/article/10.1... Findings suggest limited benefit to sequential ADC use

The Post-ASCO 2025 GU Cancer Highlights virtual webinar by @VJOncology WATCH NOW On Demand 👉 bit.ly/3UmZI7Q Featuring expert presentations and discussions on key GU cancer abstracts from ASCO 2025. @neerajaiims @ERPlimackMD @AndreaNecchi

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) Out on Lancet Oncology www.sciencedirect.com/science/arti... The long-term analysis of the PORTEC-3 trial evaluated adjuvant chemoradiotherapy versus radiotherapy

The utility of artificial intelligence in gastrointestinal oncology: A systematic review of randomized controlled trials acsjournals.onlinelibrary.wiley.com/doi/10.1002/... This systematic review evaluated the role of artificial intelligence (AI) in gastrointestinal oncology

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week Aug 28-Sept 4, 2025 REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa... youtu.be/maThWN36_sc @elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social

Day2⃣of #IUCS25 🇬🇧Portsmouth Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.” 📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.

Day2⃣of #IUCS25 🇬🇧Portsmouth Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.” 👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx

A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹 ⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways ✅ Feasible in selected patients, with potential for long-term disease control ✅ Reduced toxicity burden vs continuous therapy 📊 Stronger evidence with ICI than TKI

A Great Day One of #IUCS25 Great Presentation by Dr. Partha Choudhury The Theranostic Revolution ✨ Early randomized results look promising 🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery #ProstateCancer

A Great Day One of #IUCS25 Translating Trial endpoints into clinically meaningful decision by Dr. Alison Tree 💡 Key Takeaway: Oncology isn’t just about OS at all costs. ✅ Center decisions on what matters most to the patient in front of you ✅ Prioritize QOL, not just survival curves

Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006) ascopubs.org/doi/abs/10.1... This study evaluated the use of a deep learning model applied to shear wave elastography (AI-SWE) for improving the diagnosis of BI-RADS 3 and 4 breast masses.

Oncology: Here & Now is BACK withSeason 2 Discussing #ProstateCancer ⭐ WATCH HERE👉 youtu.be/FSrJ5iL3F-c Join Dr. Barbara Melao 🇧🇷& Dr. Danny Mena 🇲🇽 on this Great Webcast as they discuss: ✅Rationale between BULLSEYE🎯 Trial ✅Difference Between Lutetium & Terbium ✅Affinity🆚Toxicity ✅PSMA PET

Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial www.sciencedirect.com/science/arti...

TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4) www.sciencedirect.com/science/arti...

NEWS FROM INDUSTRY: monarchE Update Source Lilly investor.lilly.com/news-release... Eli Lilly announced that the Phase 3 monarchE trial has met its primary overall survival (OS) endpoint,

Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial www.annalsofoncology.org/article/S092... The 10-year follow-up of the CHAARTED trial #ProstateCancer

The Post-ASCO 2025 GU Cancer Highlights virtual webinar by @VJOncology WATCH NOW On Demand 👉 bit.ly/3UmZI7Q Featuring expert presentations and discussions on key GU cancer abstracts from ASCO 2025.

Welcome to THIS Weeks @oncoalert @vjoncology JOURNAL CLUB: Brain Mets in #BreastCancer 👉 youtu.be/oZiYqHnKBYk?... A pleasure to present Dr. @elenalaakmann of University Medical Center Hamburg-Eppendorf discussing her paper on Brain imaging screening in metastatic Breast Cancer

Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨 buff.ly/KVngjav Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates

Pre-Operative Versus Post-Operative Fractionated Stereotactic #Radiotherapy : A Single Institution Analysis of 534 Resected Metastases www.redjournal.org/article/S036... This single-institution cohort study evaluated 534 resected brain metastases 🧠 treated with either pre-op or post-op☢️(FSRT)

High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell #LungCancer With Brain Metastases jamanetwork.com/journals/jam... This phase 2 nonrandomized clinical trial conducted across 10 centers in China evaluated the efficacy and safety of high-dose aumolertinib

Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma www.sciencedirect.com/science/arti... This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 15-21, 2025 youtu.be/4DAcGeK-Qac REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

You're invited to watch the Post-ASCO 2025 Lung Cancer Highlights webinar by @VJOncology 🫁 Watch Here 👉 bit.ly/4o14fdK Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.

Join us at #GI26 to learn about the latest diagnostic and therapeutic strategies in GI cancers to transform your patient outcomes in a program planned by and featuring multidisciplinary experts. Register today: brnw.ch/21wV49s

🎥 Angeles Secord, MD, from @dukehealth.bsky.social addresses sequencing challenges of ADCs in ovarian cancer. With FDA approvals for mirvetuximab soravtansine and T-DXd, trials are essential for guiding target and payload choices. 🔗https://buff.ly/q23sXHU #ESMOGynae25 #Gyncsm #GynOnc #ImmunoOnc

Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨 buff.ly/KVngjav Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI

Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial acsjournals.onlinelibrary.wiley.com/doi/10.1002/...

Join Our Collaborators at @SpringerIME to explore this new, FREE clinical pathway tool designed to help you detect and target NTRK fusions🧬 & HER2 mutations in #NSCLC 🫁 #LungCancer CLICK HERE👉https://buff.ly/FeMbJ0r

@weoncologists.bsky.social summarizes the @oncoalert.bsky.social round-up 🤠 #SuppOnc dataon #GA the pillar assessment for #olderadults #GIonc includes #agnostic treatments in #dMMR cancer 🧬 Be sure to not miss an update by signing up 🔗: oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...

Excellent conference! Highly recommend! Total Health’s 2025 ASCO Direct @swog.org @ascocancer.bsky.social @oncoalert.bsky.social #breastcancer #cancer #clinicaltrials #bcsm #ASCODirect25

🚨 NEW #VJOncoAlert Journal Club episode from @vjoncology.bsky.social and @oncoalert.bsky.social 🚨 @silkegillessen.bsky.social discusses the addition of metformin to the SOC in mHSPC in the STAMPEDE trial! 📷Watch here: tinyurl.com/4knvf3ka 📔Read here: tinyurl.com/5fbjnsk3

@oncoalert.bsky.social @ascocancer.bsky.social #oncologynursing #oncsky

📢 Registration is now open for EBCC-15! 📍 Barcelona | 25–27 March 2026 Join us in shaping the future of multidisciplinary breast cancer care event.eortc.org/ebcc15/indiv... #EBCC15 #BreastCancer #Oncology #BCSM @oncoalert.bsky.social @europadonna.bsky.social

NEW #VJOncoAlert Journal Club with @oncoalert.bsky.social Tackling "unresectable" high-risk stage III #NSCLC with Biagio Ricciuti from @danafarbernews.bsky.social Watch 📹: tinyurl.com/ev5usd29 Read 🔖: tinyurl.com/3jafzs23 #LungCancer #LCsm

We have agency. We can speak up. We can show up. Advocating for cancer care means speaking to legislators, bringing patient stories to the front lines of policymakers, supporting & amplifying each other to continue to do the work that changes outcomes. ➡️ @oncoalert.bsky.social @statnews.com

#BreastCancer @oncoalert.bsky.social update: Predict added #radiation to their #bcsm recurrence risk & OS calculator. They rec you use a left sided mean heart dose 2Gy if you don't know ☢️ specifics. Without #radonc input this has a high likelihood of either over or under estimating risk.

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results www.nature.com/articles/s41...